title: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.
authors.affiliation: Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo 1040045, Japan.
authors.forename: Kazushi
authors.initials: K
authors.lastname: Yoshida
authors.affiliation: Gastrointestinal Oncology Division, National Cancer Center Hospital, Chuo-ku, Tokyo 1040045, Japan.
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Yamada